Trial of a new drug combo for a rare type of lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug (tarlatamab) combined with chemotherapy and immunotherapy for people whose lung cancer has changed from one type (adenocarcinoma) to small cell lung cancer after treatment with EGFR targeted therapy. The goal is to see if this combination is safe and works well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have small cell lung cancer that has not been treated before.
- You must have had an EGFR mutation (L858R or Del 19) and taken an EGFR targeted therapy.
- Your cancer must have changed to small cell lung cancer right after your EGFR treatment stopped working.
- You must be 19 years or older and able to do daily activities with little help (ECOG 0 or 1).
- You must have adequate organ function (kidney, liver, blood, heart, and lungs) as checked by blood tests and scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding a new drug, iadademstat, to standard immunotherapy drugs (atezolizumab or durvalumab) for people with small cell lung cancer that responded to initial treatment. The goal is to see if this combination works better at preventing cancer from returning.
This trial tests a new combination treatment (ABBV-706 plus atezolizumab) as a first option for people with extensive stage small cell lung cancer. It compares this new approach to the usual standard treatment, aiming to see if it works better and has fewer side effects.
This study tests three experimental drugs (tarlatamab, ZL-1310, and sometimes an immune-boosting drug) together to treat small cell lung cancer. The goal is to see if this combination can slow or shrink the cancer and help you live longer.
This trial tests a new study medicine, PF-08634404, combined with chemotherapy for people with extensive-stage small cell lung cancer. It aims to see if this combination works better than standard treatments.
This trial tests a new combination of two drugs for people with extensive-stage small cell lung cancer that has progressed after initial treatment. The goal is to see if this combination can help control the cancer.
This trial tests a combination of two newer drugs (sacituzumab tirumotecan and anlotinib) for people with extensive-stage small cell lung cancer that has progressed after one prior treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
Hear when a new Small Cell Carcinoma of Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.